FDA Accepts LEQEMBI (Lecanemab-Irmb) Biologics License Application For Subcutaneous ...
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...
Le Lézard16 小时
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European ...
Acadia Pharmaceuticals Inc. today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett ...